TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01321125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacterial culture of the prepared skin's areas
Description: Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preparing skin's areas to be tested
Description: Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antiseptic substantivity
Description: Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
Study: NCT04572607

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The consumption of avocado honey was analyzed
Description: The subjects of honey group consumed 25 g of honey each day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The consumption of avocado honey was analyzed
Description: The subjects of honey group consumed 25 g of honey each day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The consumption of avocado honey was analyzed
Description: The subjects of honey group consumed 25 g of honey each day for 4 weeks.
Study: NCT03846856

Intervention type: OTHER
Intervention: Biopsy
Description: Biopsy taken during surgical procedure
Study: NCT00575003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYT003-QbG10
Description: 6 subcutaneous injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CYT003-QbG10
Description: 6 subcutaneous injections
Study: NCT00667381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)
Description: Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
Study: NCT03558503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UGN-102
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL).
Study: NCT03216499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIF-2alpha Inhibitor PT2385
Description: Given PO
Study: NCT03716856

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cells
Description: Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied.
Study: NCT03706300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guaifenesin and Pseudoephedrine Hydrochloride Extended Release Tablets 1200/120 mg
Study: NCT01716455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184
Study: NCT01111279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpASIT+TM
Description: 1 subcutaneous injection every 7 days, during 29 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gpAST+TM/adjuvant
Description: 1 subcutaneous injection every 7 days, during 29 days

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: 1 subcutaneous injection every 7 days, during 29 days
Study: NCT01753401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar
Description: Acthar is given by subcutaneous (SC) injection (shot under the skin), at a dose of 40 units daily or 80 units every other day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as Acthar, and is given by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains the same inactive ingredients as Acthar, and is given by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Drug
Description: The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Steroid Drug
Description: The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Drug
Description: The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Drug
Description: The patient's steroid regimen 7.5 to 30 mg/day of prednisone or equivalent, chronic/stable within the 4 weeks prior to screening.
Study: NCT00610389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: immunotherapy with dendritic cells
Description: We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
Study: NCT02816463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LMA Supreme
Study: NCT00545103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476, MMX™ mesalazine, 1.2g extended release tablet
Description: SPD476 1.2g administered Once Daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476, MMX™ mesalazine, 2.4g extended release tablet
Description: SPD476 2.4g administered Once Daily (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD476, MMX™ mesalazine, 4.8g extended release tablet
Description: SPD476 4.8g administered Once Daily (QD)
Study: NCT05333900

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plant-Based Diet then animal-based diet
Description: Participants started with plant based diet: high in fiber, low in animal products for 7 days, with 14 day washout period between interventions. Following that, participants were switched to animal-based diet: high in animal products, low in fiber for 7 days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animal-based diet then plant-based diet
Description: Participants were started with animal-based diet: high in animal products, low in fiber for 7 days, with 14 days washout period between interventions. Following that, participants were switched to plant-based diet: high in fiber, low in animal products for 7 days
Study: NCT04608500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX103 minocycline foam 1.5%
Description: Dosage form description: Foam containing minocycline HCl 1.5%. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 7.5 mg (1.5% active) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle foam
Description: Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study: NCT03716856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion
Study: NCT02695745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V116517 aqueous suspension
Description: 300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib capsules
Description: 400 mg (2 capsules of 200 mg each) taken orally x 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
Study: NCT02674867

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Study: NCT03382535

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Voice therapy
Description: Voice therapy with direct and indirect therapy elements.
Study: NCT04324021

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Emapalumab
Description: I.v. infusion every third day

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Daily i.v. infusion
Study: NCT03382535

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice therapy with carryover strategies
Description: Voice therapy with direct and indirect therapy elements and supplementary tasks and reminders.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: No therapy during eight weeks. After the control period half of the group will be provided with Voice therapy and half with Voice therapy with carryover strategies.
Study: NCT05062226

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PKU/TYR GMP Protein Substitute
Description: After a 1-day baseline period during which patients will consume their usual protein substitute, each patient will receive one the case study product for 4 weeks (28 days).
Study: NCT02695745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin
Description: 1% administered topically

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin
Description: 1% administered topically

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin
Description: 1% administered topically
Study: NCT03666923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 dose level 1
Description: single intravitreal injection of THR-687 dose level 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 dose level 2
Description: single intravitreal injection of THR-687 dose level 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-687 dose level 3
Description: single intravitreal injection of THR-687 dose level 3
Study: NCT04148950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compression Stockings
Study: NCT03216499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies
Study: NCT00004126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT00486525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yoga Therapy
Description: Patients will undergo yoga therapy
Study: NCT03169088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coaching procedure
Description: In this study, the volunteers will be followed during one year.~The wellbeing will be followed with :~* survey like FFQ, IPAQ, SF36, dietary habits.~* actimetry measurement~* one year follow-up of weight, waist measurement~* nutritional biomarkers
Study: NCT03649997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
Study: NCT03265132

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anakinra
Description: sub cutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sub cutaneous injection
Study: NCT01407874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulodesine (BCX4208) 5 mg
Description: Oral dose administered daily for 84 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulodesine (BCX4208) 10 mg
Description: Oral dose administered daily for 84 days.
Study: NCT02833727

Intervention type: OTHER
Intervention: Smoking
Description: Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.

Intervention type: OTHER
Intervention: Smoking
Description: Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
Study: NCT03645161

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rat and mouse skin test
Description: Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rat and mouse skin test
Description: Comparison between local and imported skin prick testing result of rat and mouse allergen extracts in respiratory allergy patients
Study: NCT03420040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QS-M Needle Free Injector
Description: The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glargine pen
Description: The subjects were proficient in the two injection methods of injection of QS-M needle free syringe and Glargine pen injection
Study: NCT04148950

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Program
Study: NCT01157507

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravesical injection of Botulinum A Toxin
Description: One treatment, 100 U vials diluted in 10 ml normal saline

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bladder overdistension
Description: Bladder overdistension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single injection of placebo
Study: NCT01170182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Delayed Release Capsules 40 mg

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prilosec® 40 mg
Description: Prilosec® 40 mg
Study: NCT03632278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness psychoeducation Programme
Description: A MBPP will be conducted for 2 hours for each session, one a week for eight weeks. The protocol has been developed based on the model of mindfulness-based stress reduction proposed by Kabat-Zinn (1994) and Tong et al. (2015), and the psychoeducation programmes by Chien and Lee, and Lehman and colleagues (Chien \& Lee, 2010; Kabat-Zinn et al., 1992; Lehman et al., 2004; Tong et al., 2015).~The programme will be integration of mindfulness and psychoeducation to cultivate the client's mindfulness attitude. The clients will learn to apply the mindfulness in illness management and daily difficulties.
Study: NCT02451410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity
Description: The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
Study: NCT03562039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: M-MIST
Description: minimal invasive surgical technique without thorough removal of granulation tissue

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: M-MIST
Description: minimal invasive surgical technique without thorough removal of granulation tissue
Study: NCT04375488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: 60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training
Description: 60 minutes resistance exercise training for 8 major muscle groups (quadriceps, hamstring, biceps, triceps, pectoralis major, gluteus medius , gluteus maximus, middle part of deltoid) for 8 weeks, 3 times per week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: with % 30 of MIP, 20 minutes inspiratory muscle training for 8 weeks, 3 times per week
Study: NCT02385266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for D-cycloserine)
Description: Lactose filled capsules to mimic DCS 200mg capsules
Study: NCT04782856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: levothyroxine sodium tablet for oral use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: levothyroxine sodium tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Liothyronine sodium tablets for oral use treatment of hypothyroidism

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: inert sugar tablets for oral use blinding for treatment of hypothyroidism
Study: NCT00112658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study: NCT01192581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch 130/0.4 and sodium chloride injection
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch 130/0.4 and sodium chloride injection
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
Study: NCT00112658

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study: NCT02539381

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Formal Perimetry (Goldman or Octopus visual Field)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Albert's visual inattention test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Star cancellation visual inattention test

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Visual field assessment to confrontation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Visual inattention assessment to bilateral stimuli

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital tumbling E visual accuity assessment

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital visual field assessment

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital line crossing assessment

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital shape cancellation assessment
Study: NCT02564614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7070179
Description: RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.